Error loading player: No playable sources found
5545
Pancreatic Cystic Neoplasms, IPMN and Neuroendocrine Tumors (Clinical)
Date
May 6, 2025
This product is not available for individual purchase, but it is available as part of the following products:
Don't miss the opportunity to access the latest research and discoveries in the field of digestive diseases. DDW On Demand is a valuable and convenient way to enhance your knowledge and skills in digestive disease care…
Society: AGA
This abstract based session will review recent research in the evaluation and management of these conditions. Attendees will gain insights into the impact of Belzutifan on pancreatic cystic lesions and neuroendocrine tumors in Von Hippel-Lindau disease, the role of next-generation sequencing in changing management strategies, and the safety and efficacy of EUS-guided radiofrequency ablation for BD-IPMNs. Additionally, the session will cover surveillance outcomes in elderly patients, progression of sub-centimeter pancreatic cysts in diabetic patients, and differentiation of main duct-IPMN from chronic pancreatitis-related dilated pancreatic duct.
This abstract based session will review recent research in the evaluation and management of these conditions. Attendees will gain insights into the impact of Belzutifan on pancreatic cystic lesions and neuroendocrine tumors in Von Hippel-Lindau disease, the role of next-generation sequencing in changing management strategies, and the safety and efficacy of EUS-guided radiofrequency ablation for BD-IPMNs. Additionally, the session will cover surveillance outcomes in elderly patients, progression of sub-centimeter pancreatic cysts in diabetic patients, and differentiation of main duct-IPMN from chronic pancreatitis-related dilated pancreatic duct.
Moderators
Johns Hopkins Hospital
The Ohio State University Medical Center
Related Products
